6月5日，礼来盘中上涨3.01%，报1159.075美元/股，成交额16.86亿美元，续刷纪录新高。
消息面上，近期礼来密集释放利好：公司拟以70亿美元收购Kelonia布局体内CAR-T领域，与Ascidian敲定总额上限19亿美元的RNA外显子编辑合作开发肾脏病创新药，同时宣布将德国原定23亿欧元投资缩减五成，转投美国宾夕法尼亚州新建生产园区，优化全球产能布局。公司首席并购负责人表示，依托GLP-1减肥药充沛现金流，礼来并购扩张意愿达到历史峰值。多项利好共振下，股价延续强势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.